Associated Papers
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.
Shi Y et al.
Signal Transduction and Targeted Therapy, 2025
41326340 (PubMed )
Supplement: 41392_2025_2481_MOESM1_ESM.docx
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients.
Smolenschi C et al.
Npj Precision Oncology, 2025
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.
Sun F et al.
Lung Cancer (amsterdam, Netherlands), 2025
Molecular characterization of Chinese patients with small bowel adenocarcinoma.
Jin B et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024
Environmental and sex-specific molecular signatures of glioma causation.
Claus EB et al.
Neuro-oncology, 2022
Molecular profiling of clear cell adenocarcinoma of the urinary tract.
Lin CY et al.
Virchows Archiv : an International Journal of Pathology, 2019
Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Illei PB et al.
Oncotarget, 2017
29228562 (PubMed )
Supplement: oncotarget-08-96684-s002.docx
Select a paper to view details